Glycostem announced they entered into Material Transfer Agreement with , Glycostem will have access to Pieris’ Anticalin® to study the strengthened cancer-killing ability combined with Glycostem’s oNKord® in the treatment of solid tumors. The parties are also exploring unique CAR-NK treatments using Glycostem’s CAR-NK technology, viveNK™, and Pieris’ Anticalin platform to investigate new tumor-targeting approaches.

Read the full press release here.